2018³â Á¦31ȸ ´ëÇѺñ´¢±âÁ¾¾çÇÐȸ Á¤±âÇмú´ëȸ ¹× ÃÑȸ : 2018-08-25±³À°ÀÏÀÚ : 2018-08-25
±³À°Àå¼Ò : »ï¼º¼¿ïº´¿ø ¾Ïº´¿ø B1 ´ë°´ç
±³À°ÁÖÁ¦ :
2018³â Á¦31ȸ ´ëÇѺñ´¢±âÁ¾¾çÇÐȸ Á¤±âÇмú´ëȸ ¹× ÃÑȸ ÁÖÃÖ±â°ü : ´ëÇѺñ´¢±âÁ¾¾çÇÐȸ
´ã´çÀÚ : ±èÀºÁÖ
¿¬¶ôó : 02-704-8574
À̸ÞÀÏ :
app@app2010.com ±³À°Á¾·ù : ºñ´¢±â°ú
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 4Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 5 ½Ã°£ 50ºÐ
¼¼ºÎ¼ö°·á : 30,000¿ø
ºñ°í »çÀüµî·Ï 3¸¸¿ø, ÇöÀåµî·Ï 4¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 08¿ù 25ÀÏ 08:30~09:00 Registration ()
±âŸ 08¿ù 25ÀÏ 09:00~09:05 President's Welcome ()
±âŸ 08¿ù 25ÀÏ 09:05~09:10 Congratulatory Remarks ()
±³À°½Ã°£ 08¿ù 25ÀÏ 09:10~10:10 Podium Session I: Prostate Cancer ()
±³À°½Ã°£ 08¿ù 25ÀÏ 10:10~10:30 The Debilitating Impact of Bone Complications in mCRPC Dr. Alan(So (UBaCn cVouver Prostate Centre, Canada)
ÈÞ½Ä 08¿ù 25ÀÏ 10:30~10:50 Coffee Break ()
±³À°½Ã°£ 08¿ù 25ÀÏ 10:50~11:05 Active Surveillance for Low Risk Nonmuscle Invasive Bladder Cancer: When and How? Á¤½ÂÀÏ(Àü³²ÀÇ´ë)
±³À°½Ã°£ 08¿ù 25ÀÏ 11:05~11:20 Management of Recurrent Nonmuscle Invasive Bladder Cancer after Adequate BCG or Mtomycin ½É¸í¼±(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 08¿ù 25ÀÏ 11:20~11:35 Long-term Outcomes after Bladder-preserving Tri-modal Therapy versus Radical Cystectomy for Muscle-invasive Bladder Cancer: Update ÇÔ¿ø½Ä(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 08¿ù 25ÀÏ 11:35~11:50 The Role of Neoadjuvant Chemotherapy: Who Will Benefit? ±¸ÀÚÇö(¼¿ïÀÇ´ë)
±³À°½Ã°£ 08¿ù 25ÀÏ 11:50~12:20 The Significance of Testosterone and Gonadotropin Suppression in Advanced Prostate Cancer Treatment Dr. Peter Busch ¨ªstergren(Herlev and Gentofte Hospital, Denmark)
±âŸ 08¿ù 25ÀÏ 12:20~12:25 Àü¸³¼±¾Ï Áø·á±Ç°í¾È ¹ß°£ ±â³ä½Ä ()
½Ä»ç 08¿ù 25ÀÏ 12:25~13:20 Lunch (Àüü »çÁø ÃÔ¿µ) ()
±âŸ 08¿ù 25ÀÏ 13:20~13:40 ¿¬¼öº¸°íȸ ()
±âŸ 08¿ù 25ÀÏ 13:40~14:00 Project 2017 Report / 2018 Proposal ()
±³À°½Ã°£ 08¿ù 25ÀÏ 14:00~15:00 Podium Session II: Bladder and Renal Cancer ()
ÈÞ½Ä 08¿ù 25ÀÏ 15:00~15:20 Coffee Break ()
±³À°½Ã°£ 08¿ù 25ÀÏ 15:20~16:20 Podium Session III: Prostate Cancer ()
±³À°½Ã°£ 08¿ù 25ÀÏ 16:20~16:35 Genomic Analysis in Prostate Cancer: Where Are We? °¹Î¿ë(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 08¿ù 25ÀÏ 16:35~16:50 Androgen Receptor Variants in Prostate Cancer: Where Are We? ÇÏÈ«±¸(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 08¿ù 25ÀÏ 16:50~17:05 Management of Oligometastatic Prostate Cancer from Imaging to Therapy ±è¸í±â(ÀüºÏÀÇ´ë)
±³À°½Ã°£ 08¿ù 25ÀÏ 17:05~17:20 Androgen Receptor (AR) Targeted Therapy for Non-metastatic Castration-resistant Prostate Cancer (CRPC) Á¤À翵(±¹¸³¾Ï¼¾ÅÍ)
±âŸ 08¿ù 25ÀÏ 17:20~17:50 2018 KUOS Annual Business Meeting ()
±âŸ 08¿ù 25ÀÏ 17:50~18:00 ()